We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
StemPrintER platform may disrupt breast cancer prediction. The genomics-based expression analysis underlying the original StemPrintER approach consists of a proprietary 20-gene stem cell signature derived from the transcriptional profile of normal mammary stem cells. This is capable of identifying breast cancers denoting poor
prognoses via in silico analysis (i.e., using an algorithmic method).
SPARE is an evolutionary iteration of this strategy, adding two wellestablished predictive clinicopathological parameters—lymph nodal status and tumor size—to the same 20-gene signature. A subset of five genes within this signature panel has been shown to retain similar predictive value, indicating that further optimization of the approach even beyond SPARE could be achieved.
Spinout should create added incentive to own Tiziana shares. We anticipate that the envisaged spinout shall permit Tiziana shareholders of record at the point of the spinout to receive shares of the new StemPrintER-focused entity in a pari passu manner. We note that evidence showing the superiority of StemPrintER to Oncotype DX should establish a reference for the future valuation of the StemPrintER entity, since Oncotype DX was the sole product of Genomic Health— a molecular diagnostics firm that was acquired by EXACT Sciences (EXAS; not rated) last year in a $2.8B cash-plus-stock transaction
($1.1B in cash and $1.7B in EXACT common stock). In conservatively ascribing a value of only 10% of the valuation of Genomic Health at the time of its acquisition by EXACT to StemPrintER, the future spinout entity dedicated to genomics-based personalized medicine could command a price tag of $280M. Since Tiziana currently trades at a market cap well below this level (roughly $200M), we see the future spinout of StemPrintER as a possible creator of additional shareholder value, a driver of a potential arbitrage opportunity and a derisking mechanism for current or near-term Tiziana shareholders. In effect, the prospect of receiving StemPrintER entity shares on a oneto-one basis could position Tiziana shareholders to obtain all future value creation stemming from Tiziana's entire portfolio of proprietary,
innovative therapeutic candidates as upside. Our valuation and price target on Tiziana do not include any contribution from the StemPrintER platform. In anticipation of the StemPrintER spinout and near- and medium-term catalysts from Tizana's pipeline, we reiterate our Buy rating and 12-month price target of $25.00 per American Depositary Share (ADS) on TLSA. Investors should note that our price target on Tiziana's ADSs reflects the per-share price objective of £5.00 that we
placed on the company's ordinary shares, which trade in London
StemPrintER Value Driver; COVID-19 Context; Pipeline Updates; Reiterate Buy
StemPrintER and SPARE validation data presentation today. In a poster slated to be presented this morning at the virtual American Society for Clinical Oncology (ASCO) 2020 Annual Meeting, scientists shall present the results of a comparative study benchmarking the StemPrintER and SPARE (together referred to as StemPrintER) genomics-based personalized medicine approaches against Oncotype DX, a well-known diagnostic test used to predict the likelihood of breast
cancer recurrence. In our view, this constitutes a key potential value driver for current and future Tiziana shareholders, as the Board of Directors has already indicated that it plans to advance an initiative to spin out StemPrintER into a separate, standalone company.